{
  "id": 11069353,
  "title": "Novo Is Open to Acquisitions. Here Are 2 Companies That Would Be Great Candidates to Buy",
  "url": "https://urgent.news/2026/09/30/novo-is-open-to-acquisitions-here-are-2-companies-that-would-be-great-11069353",
  "topic": "finance",
  "section": "Finance & Markets",
  "published": "2026-09-30T23:10:00.000Z",
  "source": {
    "name": "Motley Fool",
    "slug": "motley-fool",
    "url": "https://www.fool.com/investing/2026/09/30/novo-is-open-to-acquisitions-here-are-2-companies/?source=iedfolrf0000001"
  },
  "original_language": "en",
  "account": "Novo Nordisk, a leading pharmaceutical company, faces challenges due to increasing competition in its diabetes and obesity drug markets. With new drugs expected to enter the field in the coming years, the company could be at risk of further decline. However, Novo Nordisk possesses a promising pipeline of drugs. To bolster this pipeline, the company may explore licensing deals or acquisitions. Recently, Novo Nordisk acquired three obesity-related assets from Kallyope, a privately held biotech firm. If the company decides to pursue additional acquisitions, two potential targets are Kailera Therapeutics and Viking Therapeutics.",
  "summary": "Could this be what Novo needs to turn things around?",
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 2,
    "also_reported_by": [
      {
        "outlet": "Nasdaq Markets",
        "title": "Novo Is Open to Acquisitions. Here Are 2 Companies That Would Be Great Candidates to Buy",
        "url": "https://urgent.news/2026/09/30/novo-is-open-to-acquisitions-here-are-2-companies-that-would-be-great",
        "published": "2026-09-30T23:30:00.000Z"
      }
    ]
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}